Wordt geladen...
Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib. As more on...
Bewaard in:
| Gepubliceerd in: | Oncologist |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Inc.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964123/ https://ncbi.nlm.nih.gov/pubmed/31575788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0229 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|